Novo Nordisk resubmits higher-dosage Ozempic application to the FDA

After Novo Nordisk's previous FDA application was returned due to missing data, the firm has resubmitted a label expansion application for Ozempic on the world's largest market for diabetes products.

Photo: Stine Tidsvilde

On Friday, Novo Nordisk announced in a company statement that it has once again applied to the US Food and Drug Administration (FDA) for permission to start marketing the weekly diabetes treatment Ozempic in a higher dosage.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs